References
- Al-Quteimat OM, Mustafa Amer A. The impact of the COVID-19 pandemic on cancer patients. Am J Clin Oncol. 2020;43(6):452–455.
- Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2021;72(2):340–350.
- Paul S, Rausch CR, Jain N, et al. The tissue issue: when to biopsy persistent or refractory disease in classic Hodgkin lymphoma. Acta Haematol. 2021;144(2):130–131.
- He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. Leukemia. 2020;34(6):1637–1645.
- Malard F, Genthon A, Brissot E, et al. COVID-19 outcomes in patients with hematologic disease. Bone Marrow Transplant. 2020;55(11):2180–2184.
- Challenor S, Tucker D. SARS-CoV-2-induced remission of Hodgkin lymphoma. Br J Haematol. 2021;192(415):10–1111.
- Buckner TW, Dunphy C, Fedoriw YD, et al. Complete spontaneous remission of diffuse large B-cell lymphoma of the maxillary sinus after concurrent infections. Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):455–458.
- Burrows SR, Silins SL, Khanna R, et al. Cross-reactive memory T cells for Epstein–Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity. Eur J Immunol. 1997;27:1726–1736.
- D’Orsogna LJ, Amir AL, Zoet YM, et al. New tools to monitor the impact of viral infection on the alloreactive t-cell repertoire. Tissue Antigens. 2009;74:290–297.
- Starnes CO. Coley’s toxins in perspective. Nature. 1992;357:11–12.
- Lawler SE, Speranza M-C, Cho C-F, et al. Oncolytic viruses in cancer treatment: a review. JAMA Oncol. 2017;3(6):841–849.